Original Wu Yue Minenet
Highlights
On December 19, Hainan Huluwa Pharmaceutical Group submitted a Class 3 generic marketing application for Oprinone Hydrochloride Injection. The product is a best-selling cardiovascular and cerebrovascular injection, with terminal sales of more than 240 million yuan in China's public medical institutions in 2022. Since the beginning of this year, Hainan Huluwa Pharmaceutical Group has applied for more than 20 new products to be listed.
Figure 1: Hainan Huluwa Pharmaceutical Group's latest declared products
Source: CDE official website
Oprinone hydrochloride injection is indicated for short-term intravenous treatment of acute heart failure with inadequate response to other drugs. According to data from Minenet, from 2022, more and more domestic pharmaceutical companies have joined the rush to eat the product, and 10 domestic pharmaceutical companies have been approved.
Figure 2: Approval status of oprinone hydrochloride injection
Source: Minenet China Listed Drugs (MID) Database
Figure 3: Sales of Oprinone Hydrochloride Injection (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
At the terminals of China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), the sales of Oprinone hydrochloride injection continued to rise rapidly, with a sharp increase of 193.56% in 2022, with sales of more than 240 million yuan, and another 40.42% growth in the first half of 2023, with promising market potential.
Table 1: Since the beginning of this year, Hainan Huluwa Pharmaceutical Group and its subsidiaries have declared products for listing
Source: Minenet China Declaration Progress (MED) database
In 2023, Hainan Huluwa Pharmaceutical Group will work hard, and up to now, the group and its subsidiaries have approved 3 new products, including desloratadine oral solution, atomoxetine hydrochloride oral solution, and valsartan amlodipine tablets (I.). Among them, atomoxetine hydrochloride oral solution has just been approved, and it has successfully won the bid for the ninth batch of national procurement, which is expected to increase sales with the help of national procurement.
Since the beginning of this year, Hainan Huluwa Pharmaceutical Group and its subsidiaries have submitted 21 new product listing applications, of which there is no imported and domestic product for sale of ebastine oral solution, and the company will participate in the first generic competition. In addition, the company currently has no inhaler approval, and has submitted 6 new inhaler product marketing applications in 2023, and after the new products are approved to enter the market, the company is expected to become a new dark horse in the 10 billion inhaler market, which is worth looking forward to.
Source: Minenet database, CDE official website
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics, and the above sales are calculated based on the average retail price of products at the terminal. The statistics are as of December 19, if there is any omission, please correct!